Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis, Otsuka

Drug class:

PSMA inhibitor, Beta radiation emitter

Related drugs:

›

FOLH1 positive	Prostate Cancer	FOLH1 positive	Prostate Cancer	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval lutetium Lu 177 vipivotide tetraxetan Sensitive : A1	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval lutetium Lu 177 vipivotide tetraxetan Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	lutetium Lu 177 vipivotide tetraxetan Sensitive: B - Late Trials lutetium Lu 177 vipivotide tetraxetan Sensitive : B	lutetium Lu 177 vipivotide tetraxetan Sensitive: B - Late Trials lutetium Lu 177 vipivotide tetraxetan Sensitive : B
FOLH1 expression	Prostate Cancer	FOLH1 expression	Prostate Cancer	pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive: C3 – Early Trials pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive : C3	pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive: C3 – Early Trials pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive : C3
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	enzalutamide + lutetium Lu 177 vipivotide tetraxetan Sensitive: C4 – Case Studies enzalutamide + lutetium Lu 177 vipivotide tetraxetan Sensitive : C4	enzalutamide + lutetium Lu 177 vipivotide tetraxetan Sensitive: C4 – Case Studies enzalutamide + lutetium Lu 177 vipivotide tetraxetan Sensitive : C4